{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:01:22Z","timestamp":1762430482178},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2010,8,13]],"date-time":"2010-08-13T00:00:00Z","timestamp":1281657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s00393-009-0533-4","type":"journal-article","created":{"date-parts":[[2010,8,11]],"date-time":"2010-08-11T18:11:40Z","timestamp":1281550300000},"page":"601-607","source":"Crossref","is-referenced-by-count":4,"title":["Selektive Kostimulationsblockade"],"prefix":"10.1007","volume":"69","author":[{"given":"R.","family":"Alten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"M\u00e4rker-Hermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,13]]},"reference":[{"key":"533_CR1","doi-asserted-by":"crossref","unstructured":"Alegre ML, Frauwirth KA, Thompson CB (2001) T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 220\u2013228","DOI":"10.1038\/35105024"},{"key":"533_CR2","unstructured":"Alten R, Westhovens R, Kremer JM et al (2009) Gleichbleibende Sicherheit und dauerhafte Verbesserung der Krankheitsaktivit\u00e4t und des Therapieansprechens \u00fcber 7 Behandlungsjahre mit Abatacept bei Biologika-naiven RA-Patienten, DGRh-Kongress, Poster # BI.17"},{"key":"533_CR3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0008-8749(92)90250-S","volume":"144","author":"Banerjee","year":"1992","unstructured":"Banerjee S, Webber C, Poole AR (1992) The induction of arthritis in mice by the cartilage proteoglycan aggrecan: roles of CD4+ and CD8+ T cells. Cell Immunol 144:347\u2013357","journal-title":"Cell Immunol"},{"key":"533_CR4","doi-asserted-by":"crossref","unstructured":"Bigbee CL, Gonchoroff DG, Vratsanos G et al (2007) Abatacept treatment does not exacerbate chronic mycobacterium tuberculosis infection in mice. Arthritis Rheum 56:8:2557\u20132565","DOI":"10.1002\/art.22750"},{"key":"533_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0008-8749(89)90001-4","volume":"121","author":"Breedveld","year":"1989","unstructured":"Breedveld FC, Dynesius-Trentham R, de Sousa M et al (1989) Collagen arthritis in the rat is initiated by CD4+ T cells and can be amplified by iron. Cell Immunol 121:1\u201312","journal-title":"Cell Immunol"},{"key":"533_CR6","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1136\/ard.2008.091876","volume":"68","author":"Buch","year":"2009","unstructured":"Buch MH, Boyle DL, Rosengren S, Saleem B et al (2009) Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 68:1220\u20131227","journal-title":"Ann Rheum Dis"},{"key":"533_CR7","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/ard.2009.119016","volume":"69","author":"Emery","year":"2010","unstructured":"Emery P, Durez P, Dougados M et al (2010) Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 69:510\u2013516","journal-title":"Ann Rheum Dis"},{"key":"533_CR8","first-page":"681","volume":"33","author":"Emery","year":"2006","unstructured":"Emery P, Kosinski M, Li T et al (2006) Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol 33:681\u20136895","journal-title":"J Rheumatol"},{"key":"533_CR9","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1126\/science.7520604","volume":"265","author":"Finck","year":"1994","unstructured":"Finck BK, Linsley PS, Wofsy D (1994) Treatment of murine lupus with CTLA4Ig. Science 265:1225\u20131227","journal-title":"Science"},{"key":"533_CR10","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/ard.2007.085084","volume":"67","author":"Genant","year":"2008","unstructured":"Genant HK, Peterfy CG, Westhovens R et al (2008) Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 67(8):1084\u20131089","journal-title":"Ann Rheum Dis"},{"key":"533_CR11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard.2007.074773","volume":"67","author":"Genovese","year":"2008","unstructured":"Genovese MC, Schiff M, Luggen M et al (2008) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67(4):547\u2013554","journal-title":"Ann Rheum Dis"},{"key":"533_CR12","first-page":"2365","volume":"34","author":"Haggerty","year":"2007","unstructured":"Haggerty HG, Abbott MA, Reilly TP et al (2007) Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol 34:2365\u20132373","journal-title":"J Rheumatol"},{"key":"533_CR13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/ard.2003.009225","volume":"63","author":"Kraan","year":"2004","unstructured":"Kraan MC, Haringman JJ, Weedon H et al (2004) T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 63:483\u2013488","journal-title":"Ann Rheum Dis"},{"key":"533_CR14","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.21201","volume":"52","author":"Kremer","year":"2005","unstructured":"Kremer JM, Dougados M, Emery P et al (2005) Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:2263\u20132271","journal-title":"Arthritis Rheum"},{"key":"533_CR15","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","volume":"349","author":"Kremer","year":"2003","unstructured":"Kremer JM, Westhovens R, Alten R et al (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349:1907\u20131915","journal-title":"N Engl J Med"},{"key":"533_CR16","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1126\/science.1323143","volume":"257","author":"Lenschow","year":"1992","unstructured":"Lenschow DJ, Zeng Y, Thistlethwaite JR et al (1992) Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 257:789\u2013792","journal-title":"Science"},{"key":"533_CR17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","volume":"174","author":"Linsley","year":"1991","unstructured":"Linsley PS, Brady W, Urnes M et al (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561\u2013569","journal-title":"J Exp Med"},{"key":"533_CR18","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1172\/JCI118220","volume":"96","author":"Mima","year":"1995","unstructured":"Mima T, Saeki Y, Ohshima S, Nishimoto N et al (1995) Transfer of rheumatoid arthritis into severe combined immunodeficient mice. The pathogenetic implications of T cell population s oligoclonally expanding in the rheumatoid joints. J Clin Invest 96:1746\u20131175","journal-title":"J Clin Invest"},{"key":"533_CR19","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","volume":"361","author":"Miossec","year":"2009","unstructured":"Miossec P, Korn T, Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med 361:888\u2013898","journal-title":"N Engl J Med"},{"key":"533_CR20","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.10294","volume":"46","author":"Moreland","year":"2002","unstructured":"Moreland LW, Alten R, Van den Bosch F et al (2002) Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46:1470\u20131479","journal-title":"Arthritis Rheum"},{"key":"533_CR21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1172\/JCI6710","volume":"105","author":"Reynolds","year":"2000","unstructured":"Reynolds J, Tam FW, Chandraker A et al (2000) CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J Clin Invest 105:643\u2013651","journal-title":"J Clin Invest"},{"key":"533_CR22","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","volume":"67","author":"Schiff","year":"2008","unstructured":"Schiff M, Keiserman M, Codding C, Songcharoen S (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67:1096\u20131103","journal-title":"Ann Rheum Dis"},{"key":"533_CR23","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1136\/ard.2008.099218","volume":"68","author":"Schiff","year":"2009","unstructured":"Schiff M, Pritchard C, Huffstutter JE et al (2009) The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: The ARRIVE trial. Ann Rheum Dis 68:1708\u20131714","journal-title":"Ann Rheum Dis"},{"key":"533_CR24","first-page":"S46","volume":"25","author":"Sibilia","year":"2007","unstructured":"Sibilia J, Westhovens R (2007) Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol 25(Suppl 46):S46\u2013S56","journal-title":"Clin Exp Rheumatol"},{"key":"533_CR25","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1136\/ard.2008.097527","volume":"68","author":"Simon","year":"2009","unstructured":"Simon TA, Smitten AL, Franklin J et al (2009) Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 68:1819\u20131826","journal-title":"Ann Rheum Dis"},{"key":"533_CR26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM197509112931101","volume":"293","author":"Van","year":"1975","unstructured":"Van Boxel JA, Paget SA (1975) Predominantly T-cell infiltrate in rheumatoid synovial membranes. N Engl J Med 293:517\u2013520","journal-title":"N Engl J Med"},{"key":"533_CR27","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1002\/eji.1830261008","volume":"26","author":"Webb","year":"1996","unstructured":"Webb LM, Walmsley MJ, Feldmann M (1996) Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol 26:2320\u20132328","journal-title":"Eur J Immunol"},{"key":"533_CR28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/ard.2006.055111","volume":"66","author":"Weinblatt","year":"2007","unstructured":"Weinblatt ME, Schiff MH, Goldman A et al (2007) Selective co-stimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomized clinical trial. Ann Rheum Dis 66:228\u2013234","journal-title":"Ann Rheum Dis"},{"key":"533_CR29","first-page":"2162","volume":"33","author":"Weisman","year":"2006","unstructured":"Weisman MH, Durez P, Hallegua D et al (2006) Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol 33:2162\u20132166","journal-title":"J Rheumatol"},{"key":"533_CR30","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3899\/jrheum.080813","volume":"36","author":"Westhovens","year":"2009","unstructured":"Westhovens R, Kremer JM, Moreland LW et al (2009) Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: A 5-year extended phase IIB study. J Rheumatol 36:736\u2013742","journal-title":"J Rheumatol"},{"key":"533_CR31","doi-asserted-by":"crossref","unstructured":"Westhovens R, Robles M, Ximenes AC et al (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors, Ann Rheum Dis 68:1870\u20131877","DOI":"10.1136\/ard.2008.101121"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0533-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-009-0533-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0533-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:36:00Z","timestamp":1559061360000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-009-0533-4"}},"subtitle":["CTLA4-Ig (Abatacept)"],"short-title":[],"issued":{"date-parts":[[2010,8,13]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["533"],"URL":"https:\/\/doi.org\/10.1007\/s00393-009-0533-4","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,13]]}}}